
With a mifepristone safety review due by March and Senate control shifting in January, the FDA faces an extended stretch without a permanent leader.
Amy Summers, consultant at Restore Health Consulting, discusses the proposed changed to the USP 795 and 797.
In this month’s episode, we talked with Amy Summers, consultant at Restore Health Consulting, on the proposed changed to the USP<795> and <797> .
If you would like to share your Pharmacy Technician Tips, email agallagher@pharmacytimes.com!






